Bevacizumab zirconium Zr-89

DB14907InvestigationalProtein Based Therapies

Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).

Mechanism: Pharmacologically active on Vascular endothelial growth factor A, long form
Curator reviewed
Also known as: 89ZR-BEVACIZUMAB

Resolves to

Compound

UNIIB552L536ZL

Targets

P15692VEGFA

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bevacizumab zirconium Zr-89, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account